title: Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
abstract: BACKGROUND
  Cholangiocarcinoma is the most common cancer in males in Thailand. The outcome is poor although systemic chemotherapy has been used in attempts to improve disease control, quality of life and prolong survival in patient with unresectable and advanced disease.
  
  
  METHODS
  In this retrospective study the medical records of all patients diagnosed as having unresectable and metastatic cholangiocarcinoma and receiving systemic chemotherapy at Udonthani Cancer Hospital during January 2007 to December 2010 were reviewed.
  
  
  RESULTS
  Among the total of 105 patients, 21 received gemcitabine-based chemotherapy and 84 5FU-based chemotherapy. Most received platinum doublet regimens. 5FU-based regimens yielded an overall response rate (tumor control) of 23.8% and a median survival of 7.2 months while gemcitabine-based regimens yielded an overall response rate (tumor control) 19.1% and a median survival of 10.0 months.
  
  
  CONCLUSIONS
  Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ.
authors.affiliation: Medical Oncology Unit, Udonthani Cancer Hospital, Thailand.
authors.forename: Kritiya
authors.initials: K
authors.lastname: Butthongkomvong
authors.forename: Ekaphop
authors.initials: E
authors.lastname: Sirachainan
authors.forename: Supattra
authors.initials: S
authors.lastname: Jhankumpha
authors.forename: Surang
authors.initials: S
authors.lastname: Kumdang
authors.forename: On-Usa
authors.initials: OU
authors.lastname: Sukhontharot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D001653:Bile Ducts, Intrahepatic / Q000187:drug effects*; D000069287:Capecitabine; D016190:Carboplatin / Q000008:administration & dosage; D018281:Cholangiocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D010166:Palliative Care; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine